{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:47Z","timestamp":1791945947609,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Treatment recommendations for patients with hepatitis C virus (HCV) genotype (GT) 3b infection and cirrhosis remain unclear. This multicentre randomized controlled trial evaluated the efficacy of 12\u2010week treatment with sofosbuvir\/velpatasvir plus ribavirin (arm A) versus sofosbuvir\/velpatasvir\/voxilaprevir (arm B) in direct\u2010acting antiviral (DAA)\u2010na\u00efve patients with HCV GT3b with compensated cirrhosis. Patients with HCV GT3b infection and compensated cirrhosis from eight sites in China were randomised 1:1 into arms A (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200930) or B (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) for 12 weeks of treatment and 12 weeks of follow\u2010up. The primary endpoint was sustained virological response (SVR) at week 12 Posttreatment. Baseline characteristics were balanced across both arms. Seven participants did not complete treatment (arm A, 4; arm B, 3). The SVR proportions were lower in arm A (70%, 95% CI 52\u201083) than in arm B (90%, 95% CI 75\u201397) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.046) in the intention\u2010to\u2010treat analysis. Per\u2010protocol analysis showed SVR proportions of 81% (95% CI, 62\u201391) in arm A and 100% (95% CI, 88\u2013100) in arm B (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021). All five virological failures were in arm A. 98.3% (60\/61) of the participants had baseline dual resistance\u2010associated substitutions (RASs) A30K and L31M and all had dual RASs at relapse, with several new RASs emerging. Both regimens were well tolerated, with one serious adverse event in arm A. Compared to sofosbuvir\/velpatasvir plus ribavirin, 12 weeks of sofosbuvir\/velpatasvir\/voxilaprevir treatment suggests a higher SVR proportion in DAA\u2010na\u00efve patients with HCV GT3b with compensated cirrhosis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical Trial Number:<\/jats:bold>\n                    NCT05467826\n                  <\/jats:p>","DOI":"10.1002\/jmv.70709","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:09:41Z","timestamp":1763539781000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sofosbuvir\/Velpatasvir\/Voxilaprevir Versus Sofosbuvir\/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial"],"prefix":"10.1002","volume":"97","author":[{"given":"Rui","family":"Huang","sequence":"first","affiliation":[{"name":"Peking University Hepatology Institute, Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8035","authenticated-orcid":false,"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The Second Affiliated Hospital of Xi'an Jiaotong University Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Xiangya Hospital Central South University Changsha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hepatology The 3rd People's Hospital of Kunming Kunming China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Guangxi Medical University Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease The First Affiliated Hospital of Nanchang University Nanchang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zu","sequence":"additional","affiliation":[{"name":"Department of Hepatology Fourth People's Hospital of Qinghai Province Xining China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Shengjing Hospital of China Medical University Shenyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangsha","family":"Kong","sequence":"additional","affiliation":[{"name":"Peking University Hepatology Institute, Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Henan Province People's Hospital Zhengzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Wei","sequence":"additional","affiliation":[{"name":"Hepatopancreatobiliary Center, Ministry of Education Key Laboratory of Digital Intelligence Hepatology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine Tsinghua Medicine of Tsinghua University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[{"name":"Peking University Hepatology Institute, Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.Lancet Gastroenterol Hepatol2 no.3(March 2017):161\u2013176."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.016"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12398"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25311"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29837"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.09.012"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad319"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","unstructured":"EASL recommendations on treatment of hepatitis C: Final update of the series(\u2729).J Hepatol73no.5(November2020):1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25454"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30343-1"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30086-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S312902"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S385071"},{"key":"e_1_2_10_16_1","first-page":"S1","article-title":"Efficacy and Safety of Sofosbuvir\/Velpatasvir with or Without Ribavirin for 12 Weeks in Genotype 3 Hepatitis C Virus\u2010Infected Patients: A Real\u2010World Study of China","volume":"17","author":"Wei Y.","year":"2023","journal-title":"Hepat Inter"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.017"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613512"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15071489"},{"issue":"2","key":"e_1_2_10_20_1","first-page":"25","article-title":"[Analysis of the Efficacy and Safety Profile of Sofosbuvir\/Velpatasvir\/Voxilaprevir in the Treatment of Patients With Chronic Hepatitis C With Failed DAAs Therapy]","volume":"32","author":"Guo Y.","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1318"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.06.002"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13115"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14112493"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18020"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.020"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13549"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70709","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.70709","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.70709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:20:48Z","timestamp":1791944448000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.70709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/jmv.70709"],"URL":"https:\/\/doi.org\/10.1002\/jmv.70709","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70709"}}